Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial

NCT04137640 is registered in ClinicalTrials.gov with Shengjing Hospital as lead sponsor.

NCT NCT04137640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04137640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Palbociclib + Letrozole Versus Epirubicin + Cyclophosphamide and Sequential Docetaxel as Neoadjuvant Chemotherapy for Postmenopausal Estrogen Receptor-positive Breast Cancer: a Prospective Randomized Controlled Double-blind Phase IV Trial
Lead sponsor
Shengjing Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
July 19, 2021
Completion date
May 31, 2026
Enrollment
152 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer